FDA clearance enables initiation of Abpro s first clinical-stage solid tumor program Clinical trial anticipated to commence in the first half of 2026 through Abpro s global collaboration with Celltrion Burlington, Mass.
Abpro Holdings, Inc. Warrant (ABPWW) — Live Session & Technical Brief
Updated Nov 16, 2026 3:01 PM ET · Prev Close $0.01
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (+0.00%) in Equities
Abpro Holdings, Inc. Warrant (ABPWW) is trading within a tight intraday band at $0.01 (+0.00%, 0.10x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, ABPWW is outperforming the S&P 500 by +1.98%.
FDA clearance enables initiation of Abpro s first clinical-stage solid tumor program Clinical trial anticipated to commence in the first half of 2026 through Abpro s global collaboration with Celltrion Burlington, Mass.
Market & Sector Relative Strength
ABPWW outperforming the S&P 500 by +1.98%Recent ABPWW Catalyst Headlines
Verified WireIND submitted for Abp-102 Ct-P72, a HER2 CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile Abp-102 Ct-P72 represents Abpro s first IND submissi
Ct-P72 Abp-102 poster selected as one of the Top 150 abstracts out of more than 1,300 submissions at Sitc 2025 Ct-P72 Abp-102 demonstrates potent and selective anti-tumor activity in HER2-high models, including Enhertu-r
Achieved 60 reduction in operating costs through a focused cost optimization plan DiversImmune platform positioned to unlock additional pipeline value Reverse stock split supports Nasdaq compliance and positions company
1–3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $0.01 (session resistance) for directional breakout confirmation.
About Abpro Holdings, Inc. Warrant
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a …
Get Instant ABPWW Catalyst Alerts
Receive an email alert when ABPWW triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversABPWW Session & Catalyst FAQ
Why is ABPWW stock trading near flat today?
Abpro Holdings, Inc. Warrant (ABPWW) is trading within a tight intraday band at $0.01 (+0.00%, 0.10x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, ABPWW is outperforming the S&P 500 by +1.98%.
Is ABPWW stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 0.10x relative volume (low participation). Our multi-factor model currently rates ABPWW as HOLD. Review full valuation, quality, and timing signals on the ABPWW Buy or Sell Decision Brief →
What is ABPWW's intrinsic value and expected trading range?
At $0.01, ABPWW's modeled 1-to-3 session range is $0.01 – $0.01, with a key inflection level at $0.01 (session resistance). Compare current price against multi-year cash flow projections in the ABPWW Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.